Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready
The company patent portfolio for UNIVERSITAIR ZIEKENHUIS ANTWERPEN currently shows 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 6 distinct examiners and 6 distinct art units, indicating a diverse range of technical subject matter. HOLT, ANDRIAE M is the busiest examiner for the portfolio, currently overseeing 1 busiest examiner pending office action. This spread of 6 pending office actions across 6 distinct examiners suggests that the company is not facing a bottleneck with any single individual.
For a practitioner, the use of 6 distinct art units means that the prosecution strategy must be tailored to different technical standards within the Biotechnology & Pharmaceuticals field. Because 1 busiest examiner pending action is the maximum handled by any one person, the portfolio's progress is not overly dependent on HOLT, ANDRIAE M. This distribution across 6 distinct art units provides a broader base for the company's intellectual property strategy. Managing 6 pending office actions requires coordination to ensure consistent messaging across the different examiners. This profile for UNIVERSITAIR ZIEKENHUIS ANTWERPEN reflects a diversified approach to its ongoing patent prosecution efforts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (17%) |
| §101 + other | 1 (17%) |
| §103 only | 2 (33%) |
| §112 only | 1 (17%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARLEN, TAMMIE K | 1 | 75.3% | +20.8% |
| HOLT, ANDRIAE M | 1 | 49.5% | +23.0% |
| LIU, CHU CHUAN | 1 | 71.3% | +14.9% |
| HIBBERT, CATHERINE S | 1 | 58.8% | +48.6% |
| TICHY, JENNIFER M.H. | 1 | 64.6% | +34.4% |
| BERHANE, SELAM | 1 | 59.1% | +56.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19107380 | SYSTEM FOR GUIDING IMPLANTATION OF A LEAD OF AN IMPLANTABLE PULSE GENERATOR FOR TREATMENT OF A PELVIC FLOOR DYSFUNCTION AND/OR OF A PELVIC FLOOR-RELATED DISORDER | MARLEN, TAMMIE K | — |
| 18850731 | COMPUTER-IMPLEMENTED METHOD AND SYSTEM FOR DETERMINING A DEGREE OF RESPIRATORY AIRFLOW | LIU, CHU CHUAN | — |
| 18039871 | COMBINATION IMMUNOTHERAPY OF IL-15 AND CD40 AGONIST IN CANCER TREATMENT | HIBBERT, CATHERINE S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19107380 | SYSTEM FOR GUIDING IMPLANTATION OF A LEAD OF AN IMPLANTABLE PULSE GENERATOR FOR TREATMENT OF A PELVIC FLOOR DYSFUNCTION AND/OR OF A PELVIC FLOOR-RELATED DISORDER | MARLEN, TAMMIE K | — |
| 18870744 | Methods of Treating an Eye Disorder | HOLT, ANDRIAE M | — |
| 18850731 | COMPUTER-IMPLEMENTED METHOD AND SYSTEM FOR DETERMINING A DEGREE OF RESPIRATORY AIRFLOW | LIU, CHU CHUAN | — |
| 18039871 | COMBINATION IMMUNOTHERAPY OF IL-15 AND CD40 AGONIST IN CANCER TREATMENT | HIBBERT, CATHERINE S | — |
| 17757356 | OPHTHALMOLOGICAL DEVICE FOR THE TREATMENT OF LSCD AND SUBSTRATE FOR USE IN SAME | TICHY, JENNIFER M.H. | — |
| 17781583 | COMBINATION IMMUNOTHERAPY OF IL-15 AND CD40 AGONIST IN CANCER TREATMENT | BERHANE, SELAM | — |
| Art Unit | Apps |
|---|---|
| 3796 | 1 |
| 1614 | 1 |
| 3791 | 1 |
| 1658 | 1 |
| 1653 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19107380 | SYSTEM FOR GUIDING IMPLANTATION OF A LEAD OF AN IMPLANTABLE PULSE GENERATOR FOR TREATMENT OF A PELVIC FLOOR DYSFUNCTION AND/OR OF A PELVIC FLOOR-RELATED DISORDER | MARLEN, TAMMIE K | 3796 | §101§102§112 | Non-Final OA | — | Pending | Feb 27, 2025 |
| 18870744 | Methods of Treating an Eye Disorder | HOLT, ANDRIAE M | 1614 | §103 | Non-Final OA | — | Pending | Dec 02, 2024 |
| 18850731 | COMPUTER-IMPLEMENTED METHOD AND SYSTEM FOR DETERMINING A DEGREE OF RESPIRATORY AIRFLOW | LIU, CHU CHUAN | 3791 | §101 | Non-Final OA | — | Pending | Sep 25, 2024 |
| 18039871 | COMBINATION IMMUNOTHERAPY OF IL-15 AND CD40 AGONIST IN CANCER TREATMENT | HIBBERT, CATHERINE S | 1658 | §102§103§112 | Non-Final OA | — | Pending | Jun 01, 2023 |
| 17757356 | OPHTHALMOLOGICAL DEVICE FOR THE TREATMENT OF LSCD AND SUBSTRATE FOR USE IN SAME | TICHY, JENNIFER M.H. | 1653 | §103 | Final Rejection | — | Pending | Jun 14, 2022 |
| 17781583 | COMBINATION IMMUNOTHERAPY OF IL-15 AND CD40 AGONIST IN CANCER TREATMENT | BERHANE, SELAM | 1675 | §112 | Non-Final OA | — | Pending | Jun 01, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNIVERSITAIR ZIEKENHUIS ANTWERPEN has 6 pending office actions as of October 2026, spread across 6 art units and 6 examiners.
Tammie K Marlen has the most, with 1 of UNIVERSITAIR ZIEKENHUIS ANTWERPEN's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
